< Back to previous page
Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
51 - 60 of 63
- Influence of microbiota on intestinal stem cell behaviour and differentiation in inflammatory bowel diseases.From1 Sep 2012 → 30 Sep 2017Funding: FWO fellowships
- Optimizing treatment of IBD patients with anti-TNFalpha biopharmaceuticals via pharmacokinetic monitoring of trough levels and calculating the cost-effectiveness of this trough level based therapy.From1 Jan 2012 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
- The role of matrix metalloproteinases in chronic inflammatory bowel diseases: new insights and applications.From3 Nov 2011 → 31 Dec 2016Funding: IWT personal funding - strategic basic research grants
- Role of PAI-1 and TAFI in the aetiology of IBD and as prognostic marker or/and therapeutic target to prevent venous thromboembolism in IBD patients.From1 Oct 2011 → 30 Sep 2015Funding: FWO fellowships
- Functional analysis of fecal microbiota of Crohn's disease patients.From1 Oct 2010 → 30 Sep 2011Funding: BOF - Other initiatives
- Study on genetic, immunologic and microbiologic factors in the etiopathogenesis of Crohn's disease and ulcerative colitis.From1 Oct 2010 → 30 Sep 2016Funding: BOF - Concerted Research Project from 1994
- Can inhibitors of the fibrinolytic system be used either as a marker or as a target to decrease the prothrombotic state observed in IBD patients.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project
- Study of the interaction between the gut flora and the mucosal immune system in the earliest lesions of Crohn's disease in the postoperative recurrence model.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project (including WEAVE projects)
- The study of genetic, immunologic and microbiologic factors in the etiopathogenesis of Crohns disease and ulcerative colitis.From1 Oct 2009 → 31 Dec 2011Funding: BOF - Concerted Research Project from 1994
- Impact of the mucosal detoxification mechanism of hydrogen sulphide on the butyrate metabolism in ulcerative colitis.From1 Jan 2009 → 31 Dec 2012Funding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 1016
- A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.(2024)
Authors: Séverine Vermeire
Pages: 415 - 427 - Effects of fecal microbiota transplantation for recurrent Clostridium difficile infection in children on kidney replacement therapy: a pilot study(2024)
Authors: Séverine Vermeire, Jeroen Raes, Noël Knops
- Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.(2024)
Authors: Séverine Vermeire
Pages: 403 - 412 - Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply.(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 1007 - 1008 - Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.(2024)
Authors: Séverine Vermeire
Pages: 404 - 415 - Crohn's disease.(2024)
Authors: Séverine Vermeire
Pages: 1177 - 1191 - Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study(2024)
Authors: Séverine Vermeire
- A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State(2024)
Authors: Tom Hillary, Maya Imbrechts, Thomas Vanassche, Maria Garmyn, Séverine Vermeire
- Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 723 - 724 - Dysbiosis and Associated Stool Features Improve Prediction of Response to Biological Therapy in Inflammatory Bowel Disease.(2024)
Authors: Bram Verstockt, Marc Ferrante, João Guedelha Sabino, Jeroen Raes, Séverine Vermeire
Pages: 483 - 495
Patents
1 - 10 of 10
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)